The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase III trial (REFLECT trial) and those with BCLC Stage B hepatocellular carcinoma: A nationwide multicenter study in Japan

被引：0
|
作者：
Sakamoto, A. [1 ]
Kurosaki, M. [2 ]
Tsuchiya, K. [2 ]
Abe, T. [3 ]
Ogawa, C. [4 ]
Soda, T. [5 ]
Kimura, H. [6 ]
Kondo, M. [7 ]
Tsuji, K. [8 ,9 ]
Koichiro, F. [10 ]
Shigeno, M. [11 ]
Jyoko, K. [12 ]
Narita, R. [13 ]
Uchida, Y. [14 ]
Yoshida, H. [15 ]
Akahane, T. [16 ]
Kobashi, H. [17 ]
Mitsuda, A. [18 ]
Marusawa, H. [1 ]
Izumi, N. [2 ]
机构：
[1] Osaka Red Cross Hosp, Gastroenterol, Osaka, Japan
[2] Musashino Res Cross Hosp, Gastroenterol, Tokyo, Japan
[3] Maehashi Red Cross Hosp, Gastroenterol, Maehashi, Japan
[4] Takamatsu Red Cross Hosp, Gastroenterol, Takamatsu, Kagawa, Japan
[5] Fukuoka Red Cross Hosp, Hepatol, Fukuoka, Fukuoka, Japan
[6] Kyoto Daiichi Red Cross Hosp, Gastroenterol, Kyoto, Japan
[7] Otsu Res Cross Hosp, Gastroenterol, Otsu, Shiga, Japan
[8] Hiroshima Res Cross Hosp, Gastroenterol, Hiroshima, Japan
[9] Atom Bomb Survivors, Hiroshima, Japan
[10] Masuda Red Cross Hosp, Gastroenterol, Masuda, Japan
[11] Nagasaki Genbaku Res Cross Hosp, Gastroenterol, Nagasaki, Japan
[12] Matsuyama Res Cross Hosp, Hepatobiliary & Pancreat Dis, Matsuyama, Ehime, Japan
[13] Oita Red Cross Hosp, Hepatol, Oita, Japan
[14] Matsue Red Cross Hosp, Gastroenterol, Matsue, Shimane, Japan
[15] Japanese Red Cross Med Ctr, Gastroenterol, Tokyo, Japan
[16] Ishinomaki Red Cross Hosp, Gastroenterol, Ishinomaki, Miyagi, Japan
[17] Okayama Red Cross Hosp, Gastroenterol, Okayama, Japan
[18] Tottori Red Cross Hosp, Gastroenterol, Tottori, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
752P
引用
收藏
页码：289 / 289
页数：1
相关论文
共 50 条
  • [21] The efficacy of radiofrequency ablation combined with transcatheter hepatic chemoembolization for patients with BCLC stage B hepatocellular carcinoma: A multicenter retrospective study-propensity score matching
    Hirooka, Masashi
    Hiraoka, Atsushi
    Ochi, Hironori
    Koizumi, Yohei
    Kisaka, Yoshiyasu
    Tokumoto, Yoshio
    Abe, Masanori
    Joko, Kouji
    Michitaka, Kojiro
    Hiasa, Yoichi
    HEPATOLOGY, 2016, 64 : 685A - 685A
  • [22] Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN).
    Huynh, Jasmine
    Cho, May Thet
    Kim, Edward Jae-Hoon
    Ren Min
    Robbins, Carol
    Amaya-Chanaga, Carlos
    Vogel, Arndt
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [23] A Phase 2, Prospective, Multicenter, Single-arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-stage Hepatocellular Carcinoma: TACTICS-L Trial
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Saeki, Issei
    Ishikawa, Toru
    Inaba, Yoshitaka
    Morimoto, Naoki
    Aikata, Hiroshi
    Tanabe, Nobukazu
    Wada, Yoshiyuki
    Kondo, Yasuteru
    Tsuda, Masahiro
    Nakao, Kazuhiko
    Ito, Takanori
    Hosaka, Tetsuya
    Kawamura, Yusuke
    Kuzuya, Teiji
    Nojiri, Shunsuke
    Ogawa, Chikara
    Koga, Hironori
    Hino, Keisuke
    Ikeda, Masafumi
    Moriguchi, Michihisa
    Hisai, Takashi
    Yoshimura, Kenichi
    Furuse, Junji
    Arai, Yasuaki
    LIVER CANCER, 2024, 13 (01) : 99 - 112
  • [24] Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria
    Yuki Nemoto
    Hiroki Ishihara
    Kazutaka Nakamura
    Hidekazu Tachibana
    Hironori Fukuda
    Kazuhiko Yoshida
    Hirohito Kobayashi
    Junpei Iizuka
    Hiroaki Shimmura
    Yasunobu Hashimoto
    Kazunari Tanabe
    Tsunenori Kondo
    Toshio Takagi
    Targeted Oncology, 2022, 17 : 475 - 482
  • [25] Efficacy and Safety of Immunotherapy-Based Combinations as First-Line Therapy for Metastatic Renal Cell Carcinoma in Patients Who Do Not Meet Trial Eligibility Criteria
    Nemoto, Yuki
    Ishihara, Hiroki
    Nakamura, Kazutaka
    Tachibana, Hidekazu
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Kobayashi, Hirohito
    Iizuka, Junpei
    Shimmura, Hiroaki
    Hashimoto, Yasunobu
    Tanabe, Kazunari
    Kondo, Tsunenori
    Takagi, Toshio
    TARGETED ONCOLOGY, 2022, 17 (04) : 475 - 482
  • [26] Post hoc analysis in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function in the phase 3 REFLECT study of lenvatinib vs sorafenib
    Huynh, J.
    Cho, M.
    Kim, E.
    Ren, M.
    Amaya-Chanaga, C.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S123 - S124
  • [27] Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan
    Koh, Katsuyoshi
    Kato, Motohiro
    Saito, Akiko M.
    Kada, Akiko
    Kawasaki, Hirohide
    Okamoto, Yasuhiro
    Imamura, Toshihiko
    Horibe, Keizo
    Manabe, Atsushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (07) : 684 - 691
  • [28] Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: Subset analyses of the phase III Sorafenib Asia-Pacific trial
    Cheng, Ann-Lii
    Guan, Zhongzhen
    Chen, Zhendong
    Tsao, Chao-Jung
    Qin, Shukui
    Kim, Jun Suk
    Yang, Tsai-Sheng
    Tak, Won Young
    Pan, Hongming
    Yu, Shiying
    Xu, Jianming
    Fang, Fang
    Zou, Jessie
    Lentini, Giuseppe
    Voliotis, Dimitris
    Kang, Yoon-Koo
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (10) : 1452 - 1465
  • [29] IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).
    Vogel, Arndt
    Siegler, Gabriele Margareta
    Siebler, Jurgen
    Lindig, Udo
    Schultheiss, Michael
    Mueller, Tobias
    Simon, Henry
    Joeckel, Christiane
    Mueller, Daniel Wilhelm
    Al-Batran, Salah-Eddin
    Saborowski, Anna
    De Toni, Enrico N.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] Neoadjuvant hepatic arterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: A multi-center, phase 3, randomized, controlled clinical trial
    Wei, Wei
    Li, Shaohua
    Zhao, Rongce
    Cheng, Yuan
    Li, Qiang
    Lu, Lianghe
    Mei, Jie
    Shang, Changzhen
    Luo, Rui
    Pan, Mingxin
    Xiang, Bangde
    Jiang, Yuchuan
    Lei, Qiucheng
    Cao, Mingrong
    Li, Ji-Bin
    Zheng, Lie
    Chen, Huanwei
    Zhong, Jian-Hong
    Zhong, Chong
    Guo, Rongping
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345